Intellia.jpg
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
September 16, 2022 07:15 ET | Intellia Therapeutics, Inc.
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses,...
attralus-logo.png
Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis
August 08, 2022 07:00 ET | Attralus, Inc
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Intellia.jpg
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
February 28, 2022 16:01 ET | Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...
Intellia.jpg
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
February 17, 2022 07:30 ET | Intellia Therapeutics, Inc.
Fourth quarter and full-year 2021 financial results – February 24, at 8:00 a.m. ETUpdated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR)...
Intellia.jpg
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
November 22, 2021 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) --  Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has...
Intellia Therapeutics Logo
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
June 26, 2021 11:15 ET | Intellia Therapeutics, Inc.
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean...
Intellia.jpg
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
June 04, 2021 07:30 ET | Intellia Therapeutics, Inc.
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidateLate-breaking abstract selected for oral presentation on...
Intellia.jpg
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET | Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
Intellia.jpg
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
March 30, 2021 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...